Approval · Notice of Compliance 37183 · 2026
AURO-ELETRIPTAN: Notice of Compliance 37183
Issued March 25, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37183
- Date
- March 25, 2026
- Company
- Auro Pharma Inc.Woodbridge, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to an Abbreviated New Drug Submission (SANDS), supplement
- Submission class
- Other
- Reason
- Update to package labels
- Canadian reference product
- REPLAX (Pfizer Canada Ulc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AURO-ELETRIPTAN | Not yet assigned | — |
Medicinal ingredients
- ELETRIPTAN HYDROBROMIDE 20 MG per TAB
- ELETRIPTAN HYDROBROMIDE 40 MG per TAB